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a-MSH a-melanocyte-stimulating hormone 
ANP atrial natriuretic peptide 
AVP arginine vasopressin 
BNP brain natriuretic peptide 
CNP C-type natriuretic peptide 
CNS central nervous system 
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GMP guanosine monophosphate 
GRF growth hormone-releasing factor 
ICV intracerebroventricular 
IL-1 interleukin-1 
IL-6 interleukin-6 
IM intramuscular 
IP inptraperitoneal 
LPS lipopolysaccharide 
MAO monoamine oxidase 
NSAID non-steroid anti-inflammatory drug 
PACAP pituitary adenylate cyclase-activating polypeptide 
PHI peptide histidine isoleucine 
PHV peptide histidine valinamide 
RNA ribonucleic acid 
TNF tumor necrosis factor 
TRH thyrotropin-releasing hormone 
VIP vasoactive intestinal polypeptide 
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1 Introduction 
The ability to keep the body temperature relatively independent from environmental 
conditions is a fundamental part of mammalian homeostasis. Such an isolation of the living 
organism from diverse temperature impacts requires highly organized control mechanisms. 
Researches of the past few decades have come to connect these regulatory processes to the 
actions of certain mediators of inflammation in the central nervous system (CNS), particularly 
in the hypothalamus. The above-mentioned investigations were mostly aimed at the disclosure 
of the mechanisms that originate, maintain and terminate fever - a hyperthermic phenomenon, 
which has been having overriding significance in human medicine for ages - since the 
adequate influence on these thermoregulatory events could lead a number of diseases to a 
more favorable outcome. 
The discovery of the regulatory characteristics of fever has guided medicine to the 
exploration of a number of factors that affect the body temperature through action on the 
CNS. Our present ideas on the bases of fever have been derived from the late 1800s, when 
Liebermeister introduced the view of fever as a regulated body temperature. This was based 
on the observations that the warmness of the febrile subject returned to its previous level after 
experimental cooling or warming (51). Since then, considerable efforts have been taken to 
clarify the mechanisms that maintain or alter temperature regulation. 
It was the connection of fever to the inflammatory response that made the mediator 
theory a suitable approach for the investigations of thermoregulatory mechanisms. 
Hyperthermic effects of certain prostaglandins and also their presumable roles in the 
mediation of the lipopolysaccharide (LPS) -induced fever have been reported in the seventies 
(30, 70). Later on the investigations have expanded over the roles of some cytokines such as 
interleukin-1 (IL-1) (19, 77), interleukin-6 (IL-6) (40, 58) and tumor necrosis factor (TNF) 
(50, 75, 82) in thermoregulation together with other endogenous peptides that - besides their 
probable thermoregulatory actions - were known to have hormonal effects. Arginine 
vasopressin (AVP) (47, 53), a-melanocyte-stimulating hormone (a-MSH) (33, 74) and other 
endogenously produced peptides (17, 45, 64, 79, 97) that can be found in the CNS have been 
suspected of having thermoregulatory capacity. 
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Increasing evidence on a variety of neuropeptides that can affect thermoregulation 
indicate by now that more than a few pathways may believably participate in the central 
control of body temperature. The revelation of the exact modes of thermal actions of these 
peptide neurohormones could not only expand our knowledge over thermoregulatory 
mechanisms and the significance of neuropeptides in the brain but also facilitate 
understanding the function of the neuroendocrine system itself. 
1.1 The natriuretic peptide family 
The family of atrial natriuretic peptide (ANP) and related peptides currently consists 
of ANP, brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). ANP was first 
discovered in rat atrial myocardial extracts (29) and was later found in the brain (49). 
Natriuretic peptides have been found in human cerebrospinal fluid, CNP in the highest 
concentration (46). 
Studies investigating the primary structure of the ANP precursor showed that atrial 
mRNA encodes a 150-152 amino acid residue precursor molecule termed pre-pro-atrial 
natriuretic peptide. The first 23-25 N-terminal amino acid residues of pre-pro-ANP contain 
the signal peptide domain and the remaining residues comprise pro-ANP (20). Pro-ANP 
exhibits strong homology among various species (human, rat, mouse, dog and rabbit) (31). 
The circulating form of ANP in plasma consists of a smaller 3 kDa C-terminal fragment of the 
pro-hormone (66). The bioactive form of ANP is a 28 amino acid residue peptide that 
possesses a 17-residue ring structure closed by a disulphide bridge between two cysteine 
residues. The N- and C-terminals protrude from the ring and consist of six and five residues, 
respectively (Fig. 1). Active ANP has a highly conserved structure among species. 
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Figure 1 
Structure of ANP 
One letter amino acid code - A: alanine, C: cysteine, D: aspartic acid, F: phenylalanine, G: glycine, I: isoleucine, 
L: leucine, M: methionine, N: asparagine, Q: glutamine, R: arginine, S: serine, Y: tyrosine. Amino acid in gray 
circle is identical with that of BNP and CNP in the corresponding position. 
Sudoh et al. originally isolated BNP in 1988 from porcine brain (89). BNP consists of 
26 amino acids and resembles ANP in having a 17-residue ring structure closed by a 
disulphide bridge. A different form of BNP has been isolated from porcine brain. This 
contains an additional six amino acids attached at the N-terminus and has been designated 
BNP-32 (90). Pre-pro-BNP contains 131, while pro-BNP 106 amino acids. Both peptides 
have BNP at their C-terminals. An as yet uncharacterized enzyme to produce BNP and BNP-
32 cleaves pro-BNP. BNP and BNP-32 are the major tissue forms of BNP in brain (54). The 
ring structure of BNP exhibits high homology to ANP differing by only five residues (Fig. 2). 
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Figure 2 
Structure of BNP 
One letter amino acid code - A: alanine, C: cysteine, D: aspartic acid, F: phenylalanine, G: glycine, I: isoleucine, 
K: lysine, L: leucine, M: methionine, N: asparagine, P: proline, R: arginine, S: serine, T: threonine, V: valine, Y: 
tyrosine. Amino acid in gray circle is identical with that of ANP and CNP in the corresponding position. 
CNP was first isolated from porcine brain in 1990 (91). CNP is present in a number of 
tissues, such as kidney, intestine and also in cerebrospinal fluid, but unlike ANP and BNP, 
has not been found in the circulation at readily detectable concentrations (66). CNP has also 
been detected in high concentrations in the hypothalamus, where it is assumed to function as a 
neuromodulator (46, 98). The pre-pro-CNP precursor molecule consists of 126 amino acid 
residues. Pro-CNP is a 103-residue peptide, with a 22 amino acid sequence at the C-terminus 
that is identical to CNP-22 (55, 95). The amino acid sequence of CNP exhibits a high degree 
of homology to corresponding sequences of ANP and BNP. These peptides share a 17-residue 
ring structure formed by an intramolecular disulphide bridge, which is characteristic of the 
natriuretic peptide family (66) (Fig. 3). 
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Figure 3 
Structure of CNP 
One letter amino acid code - C: cysteine, D: aspartic acid, F: phenylalanine, G: glycine, I: isoleucine, K: lysine, 
L: leucine, M: methionine, R: arginine, S: serine. Amino acid in gray circle is identical with that of BNP and 
CNP in the corresponding position. 
The biological actions of the natriuretic peptides are mediated through association 
with specific, high-affinity receptors located on the surface of the target cells. Three main 
natriuretic peptide receptors have been cloned and named alphabetically: A, B and C (92). 
The A- and B-type receptors probably act via cyclic-GMP as a second messenger. The C-type 
receptor is less clearly linked to a second messenger system, and is presumed to be a 
clearance receptor (59). This latter statement about the physiological function of the C-type 
receptor is mainly based upon the findings that this receptor binds all the three peptides with 
almost equal affinity (2, 3) - although there are reports that C-type receptor can inhibit 
adenylate cyclase and affect phospholipase-C activity in some tissues (101), which raises the 
possibility that the C-type natriuretic receptor after all may have significant effect on cell 
function. The sequence of affinity for the A-type receptor is ANP > BNP > CNP, while that 
for the B-type receptor seems to be CNP > BNP > ANP (92). A new guanylyl cyclase-
uncoupled natriuretic peptide receptor named D-type receptor has been recently identified in 
the eel in addition to the A-, B- and C-type receptor, which may help to recognize the 
evolutionary changes in the natriuretic peptide system (93). 
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1.2 Natriuretic peptides and the neuroendocrine system 
Numerous studies have been undertaken to investigate the presence, distribution and 
localization of the natriuretic peptides and their receptors in the CNS, and it is recognized 
today that ANP and related peptides take part in regulatory processes in the neuroendocrine 
system. 
Relatively little is known about the actions of these peptides on the integrated 
functions of the CNS. Our Department has recently carried out systemic studies to explore the 
roles of ANP and related peptides in learning (12, 14), behavior (13) and opiate effects (5, 6, 
7). Anxiolytic properties of these peptides have also been demonstrated in an elevated plus-
maze model (15, 16). Abundant modes of action of natriuretic peptides on sites in the 
hypothalamus and pituitary have been demonstrated (65, 73, 76, 83, 84, 85), no study, 
however, has yet correlated these neuropeptides with thermoregulatory processes. Although 
the presence of natriuretic peptides and their receptors in astrocytes has been established (52, 
67, 103), no evidence exists concerning astrocytes mediating biological effects of ANP and 
related peptides. 
1.3 Natriuretic peptides - interactions with isatin 
Interactions of some members of the natriuretic peptide family with an endogenous 
indole, isatin (indole-2, 3-dione), were recently reported (32). Isatin is distributed throughout 
the CNS and is present in other tissues at levels that suggests that it has physiological effects 
(69); however, its origin and metabolic pathways are still uncertain. It selectively inhibits 
monoamine oxidase (MAO) B in vitro (32). Although its anxiogenic properties (11) and dose-
related proconvulsant and anticonvulsant activities have been demonstrated in rats (8), the 
functional significance of these phenomena is not yet known. 
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Isatin and some analogues have been found to act as antagonists on natriuretic peptide 
receptors of the brain and heart, and the possibility has therefore arisen that isatin is an 
endogenous inhibitor of these peptides at a central level (68). Although antagonism of isatin 
against some of the behavioral effects of ANP has been described (10), the mechanisms of 
interaction of isatin and the natriuretic peptide system remain to be identified (69). 
1.4 PACAP and its receptors 
Pituitary adenylate cyclase-activating polypeptide (PACAP) is known as a member of 
a superfamily that includes vasoactive intestinal polypeptide (VIP), secretin, glucagon, 
peptide histidine isoleucine (PHI), peptide histidine valinamide (PHV), helodermin, 
helospectin, gastric inhibitory polypeptide (GIP) and growth hormone-releasing factor (GRF) 
(23) (Table 1). PACAP was originally isolated from the ovine hypothalamus (71). The 
biologically active neuropeptide exists in two amidated forms: PACAP-38, a 38-amino-acid 
polypeptide; and PACAP-27, a truncated form of PACAP-38 containing 27 residues (72). It 
now appears that, in all tissues, PACAP-27 represents only a minor portion of total PACAP. 
The extreme conservation of the structure of PACAP in vertebrates means that this 
neuropeptide is subjected to strong evolutionary pressure and may play a substantial role (23). 
Both PACAP-38 and PACAP-27 are potent in stimulating adenylate cyclase. 
At least two receptor classes have been reported for PACAP in mammalian tissues: 
type I and type II. Type I receptors are highly selective in the recognition of PACAP much 
more potently than VIP, but type II receptors display similar high affinity for PACAP-27, 
PACAP-38 and VIP (21). In the CNS, type I PACAP receptors are abundant whereas the 
amount of type II receptors is low (36). Type I receptors can be divided into two, and type II 
receptors into three subtypes (23). The PACAP-A subtype of the type I receptor exhibits 
hardly any preference for PACAP-38 over PACAP-27, whereas the PACAP-B subtype 
recognizes PACAP-38 with high affinity and PACAP-27 with low affinity. 
Type II (VIP-PACAP) receptors almost exclusively interact with adenylate cyclase. At 
least two effector systems, however, exist for type I PACAP-preferring receptors (23). It 
appears that type I receptors stimulate both adenylate cyclase and phospholipase C, this 
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coupling to dual signaling cascades involving interactions with G proteins of the Gs and Gq 
types. Subsequent to phospholipase C activation and through the inositol phosphate cascade, a 
secondary Ca2+ entry elevating cytosolic [Ca2+] follows Ca2+ mobilization (23). 
Species Peptide Amino acid sequence 
o/h/r PACAP-38 H-S-D-G-I-F-T-D-S-Y-S-R-Y-R-K-Q-M-A-V-K-K-Y-L-A-A-V-
L-G-K-R-Y-K-Q-R-V-K-N-K-NH2 
O/h/p/f PACAP-27 H-S-D-G-I-F-T-D-S-Y-S-R-Y-R-K-Q-M-A-V-K-K-Y-L-A-A-V-
L-NH2 
b/do/go/h/o/p/r/ra VIP H-S-D-A-V-F-T-D-N-Y-T-R-L-R-K-Q-M-A-V-K-K-Y-L-N-S-I-
L~N-NH2 
b/p/gp/o secretin H-S-D-G-T-F-T-S-E-L-S-R-L-R-D-S-A-R-L-Q-R-L-L-Q-G-R-
V-NH2 
b/h/p glucagon H-S-Q-G-T-F-T-S-D-Y-S-K-Y-L-D-S-R-R-A-Q-D-F-V-Q-W-L-
M-N-T 
p GIP Y-A-E-G-T-F-I-S-D-Y-S-I-A-M-D-K-I-R-Q-Q-D-F-V-N-W-L-
L-A-Q-K-G-K-K-S-D-W-K-H-N-I-T-Q 
p GRF (1-44) Y-A-D-A-I-F-T-N-S-Y-R-K-V-L-G-Q-L-S-A-R-K-L-L-Q-D-I-
M-S-R-Q-Q-G-E-R-N-Q-E-Q-G-A-R-V-R-L-NH2 
Table 1 
Amino acid sequence of PACAP and some related peptides 
One letter amino acid code - A: alanine, C: cysteine, D: aspartic acid, F: phenylalanine, G: glycine, H: histidine, 
I: isoleucine, K: lysine, L: leucine, M: methionine, N: asparagine, P: proline, Q: glutamine, R: arginine, S: 
serine, T: threonine, V: valine, W: threonine, Y: tyrosine. 
Species: b: bovine, do: dog, f: frog:, go: goat, gp: guinea pig, h: human, o: ovine, p: porcine, r: rat, ra: rabbit 
1. 5 PACAP and the neuroendocrine system 
The heterogeneous distribution of PACAP in the rat central nervous system (CNS) has 
been demonstrated (26). The peptide has been observed in several nuclei of the hypothalamus, 
thalamus, ventral tegmental area, septum, amygdala and brainstem (63). PACAP-specific 
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binding sites are found throughout the rat brain (62). The presence of PACAP receptors has 
also been demonstrated in astrocytes (4, 94); however, their physiological importance is not 
clear. 
The locations of PACAP and its receptors suggest that this peptide may be involved in 
regulatory processes in the neuroendocrine system. Relatively little is known about the action 
of PACAP on the integrated functions of the CNS. Although abundant information is 
available regarding the action of PACAP on sites in the pituitary and the hypothalamus (43, 
56, 102), it appears that PACAP variously affects hormone release from anterior pituitary 
depending on the cell type and experimental conditions. Dissenting evidence exist on the 
effects of PACAP on the secretion of pituitary hormones in in vitro static (25, 71), dynamic 
(34) and in vivo systems (37). In a number of cases the dose-response curve of PACAP 
seemed bell-shaped (maybe due to desensitization at high doses) (23, 71). Delayed 
hypopthalamo-hypophiseal actions in response to PACAP may reflect the interaction of a 
second messenger, induction of an additional transduction signal and/or effects on 
transcription (23,43). 
Only a few studies have yet correlated this neuropeptide with thermoregulatory 
processes. It has been reported that PACAP counteracted reserpine-induced hypothermia in 
mice. Injections of PACAP-38 dramatically reversed the body temperature lowered by 
reserpine, and it was suggested that PACAP might have an important temperature-regulating 
function in the CNS (61). 
The above-mentioned observation prompted us to investigate the central effects of 
PACAP on body temperature. 
1.6 The aims of our experiments 
Our experiments were designed to study 
1. the effects of ANP and related peptides on the body temperature of rats; 
2. the comparison of the hyperthermic effects of the most efficacious doses of different 
natriuretic peptides in rats; 
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3. the effects of noraminophenazone on the natriuretic peptide-induced hyperthermia in 
rats; 
4. the effects of isatin on the natriuretic peptide-induced hyperthermia in rats; 
5. the effects of PAC AP-3 8 on the body temperature of rats; 
6. the effects of PAC AP-3 8 antiserum on the body temperature and on the hyperthermic 
effect of PACAP-38 in rats; 
7. the effects of noraminophenazone on the PACAP-38-induced hyperthermia in rats. 
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2 Materials and methods 
2.1 Materials 
The materials used in the experiments were of the following origins: 
• Sterile pyrogen-free saline (Natr. chlor. inj. 0.9 %, Biogal, Hungary) 
• Normal rabbit serum (this was a honorous gift from Dr. Miklós Vecsernyés, 
Department of Endocrinology Albert Szent-Györgyi Medical University, 
Szeged, Hungary) 
• Sodium pentobarbital (Nembutal, CEVA, France) 
• ANP-28, BNP-32 and CNP-22 (Bachem California Inc., Torrance CA, USA) 
• Noraminophenazone (Algopyrin, Chinoin, Hungary) 
• Isatin (indole-2, 3-dione, Sigma Chemical Co., St. Louis MO, USA) 
• PACAP-38 (Bachem, Switzerland) 
• Human PACAP-38 antiserum (PACAP-38-AB, Yanaihara Institute Inc. Japan) 
2.2 Animals 
All experiments were performed on adult male Wistar rats weighing 200 ± 30 g. The 
animals were kept in a room maintained at constant temperature (23 ± 1 °C) and on a 12-h 
dark-light cycle (lights on from 6:00 to 18:00). Commercial laboratory food and tap water 
were given ad libitum. At least a week of recovery from surgery was allowed before the 
beginning of the experiments. Each animal was used only once in the experiments. 
The animals were kept and handled during the experiments in accordance with the 
instructions of Albert Szent-Györgyi Medical University Ethical Committee for the Protection 
of Animals in Research. 
2.3 Surgery 
In order to allow intracerebroventricular (ICV) peptide administration, the rats were 
implanted with a cannula introduced into the right lateral brain ventricle before the 
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experiments. Under pentobarbital (Nembutal, 35 mg/kg), intraperitoneal (IP) anesthesia, the 
stainless steel cannula was stereotaxically inserted into the ventricle with coordinates 0.2 mm 
posterior; 1.7 mm lateral to the bregma; 3.7 mm deep from the dural surface according to the 
atlas of Pellegrino et al. (80). The cannula was secured with dental acrylic cement. Rats were 
allowed a minimum of 5 days to recover from surgery before peptide treatment. The correct 
positioning of the cannula was checked by injecting 10 pi methylene blue into the ventricle of 
decapitated animals through the cannula and subsequent dissection of the brain. Animals with 
incorrect placement of the cannula were discarded and excluded from the statistical 
evaluations. 
2.4 Measuring-instruments 
In experiments with natriuretic peptide-effects on the body temperature a digital 
electric thermometer (Model: Thermini 130) whereas in all other experiments a digital electric 
thermometer (Model: Cole-Parmer 8402-10) was used to monitor the colon temperature. 
2.5 Treatments 
2.5.1 Effects of natriuretic peptides on colon temperature 
For ICV treatment, different doses of ANP-28, BNP-32 or CNP-22 were dissolved in 
sterile pyrogen-free 0.9% saline and injected in a volume of 2 pi into the lateral brain 
ventricle of the animals. 
A pyrazolone derivative noraminophenazone was used to inhibit cyclooxygenase. 
Noraminophenazone was administered intramuscularly (IM) in a dose of 50 mg/kg, diluted in 
saline in a volume of 2.5 ml/kg. 
The control animals received the same volume of saline for all experiments. 
2.5.2 Effects of isatin on natriureticpeptide-induced hyperthermia 
Treatments with ANP-28, BNP 32 and CNP-22 were similar to the above described 
except that in accordance with our previous experience (78), only the most effective dose of 
the natriuretic peptides (1 pg) was selected. Isatin was administered IP in a dose of 50 mg/kg, 
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diluted in saline in a volume of 2.5 ml/kg. The control animals received the same volume of 
saline for all experiments. 
2.5.3 Effects of PACAP on colon temperature 
For ICV treatment, different doses of PACAP-38 were dissolved in sterile pyrogen-
free 0.9% saline and injected in a volume of 2 pi. The control groups were treated with saline 
for all experiments. 
Noraminophenazone was administered intramuscularly (IM) in a dose of 50 mg/kg, 
diluted in saline in a volume of 2.5 ml/kg. 
PACAP-38-AB was diluted with saline. The specificity of the PACAP-38-AB was as 
follows: PACAP-38 100%, PACAP-38 (5-38) 100%, PACAP-38 (10-38) 57.2%, PACAP-38 
(16-38) 173%, PACAP-38 (22-38) 333%, PACAP-27 < 0.1%, glucagon 0%, VIP 0%, PHI 
0%, secretin 0%. Different dilutions (1:5, 1:10 and 1:20) of PACAP-38-AB were injected 
ICV in a volume of 2 pi. In experiments with PACAP-38-AB, the control animals received 
the same volume of normal rabbit serum, in the respective dilutions. 
2.6 Procedures 
In order for the rats to habituate to the experimental environment, the animals were 
transferred to the laboratory 2 h before the beginning of the test, on the day of the experiment. 
The animals were kept in the laboratory at constant temperature (23.0 ± 0.5 °C) before and 
throughout the experiment. Each animal was removed from the cage and gently restrained on 
the table with a cloth. The colon temperature was monitored by inserting a vaseline-lubricated 
thermistor probe of a digital electric thermometer 5 cm into the rectum of the animal. The 
probe was inserted the same distance into the rectum each time it was used. 
The following experiments were performed: 
2.6.1 Effects of natriuretic peptides on colon temperature 
All experiments started at 8 a.m. with an initial colon temperature measurement, the 
colon temperature being measured before and 30,60 and 90 min after peptide treatment. 
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1. The effects of centrally administered ANP-28, BNP-32 and CNP-22 on body temperature 
were studied. The natriuretic peptides were injected ICV in different doses (40-1000 ng). 
2. In studies with noraminophenazone on the hyperthermic effect of the natriuretic peptides, 
noraminophenazone was administered IM once 30 min before ICV peptide treatment 
(ANP-28, BNP-32 or CNP-22 being injected in doses of either 400 ng or 1000 ng) and the 
colon temperature was measured 30,60 and 90 min later. 
2.6.2 Effects of isatin on natriureticpeptide-induced hyperthermia 
All experiments started at 8 a.m. with an initial colon temperature measurement, the 
colon temperature being measured before and 30,60 and 90 min after peptide treatment. 
1. The effects of centrally administered ANP-28, BNP-32 and CNP-22 on body temperature 
were studied. The natriuretic peptides were injected ICV in a dose of 1 pg. 
2. In studies with isatin on the hyperthermic effects of natriuretic peptides, isatin (50 mg/kg; 
IP) was administered once 30 min before ICV peptide treatment (ANP-28, BNP-32 or 
CNP-22 being injected in a dose of 1 pg) and the colon temperature was measured 30, 60 
and 90 min later. 
2.6.3 Effects of PACAP on colon temperature 
The experiments started at 8 a.m. with an initial colon temperature measurement, the 
colon temperature also being measured before and 1, 2, 3, 4, 5, 6 and 24 h after peptide 
treatment. In studies with PACAP-38-AB, colon temperature was measured before and 1, 2, 
3,4, 5, 6, 7, 8 and 9 h after PACAP-38-AB treatment. 
1. The effects of centrally administered PACAP-38 on body temperature were studied. The 
peptide was injected ICV in different doses (250 ng/55 pmol, 500 ng/110 pmol and 1000 
ng/220 pmol), and the colon temperature was measured every hour for 6 h and at 24 h after 
PACAP treatment. 
2. The effects of centrally administered PACAP-38-AB on body temperature and on PACAP-
induced hyperthermia were studied. PACAP-38-AB was dissolved in physiological saline 
in dilutions of 1:5, 1:10 and 1:20. Two pi was administered ICV 3 h before PACAP-38 
(1000 ng, ICV) or saline (ICV) injection. To ascertain the possible effects of rabbit serum, 
groups of animals received normal rabbit serum in the same dilutions and volumes as the 
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PACAP-38-AB 3 h before either ICV PACAP-38 or saline injections. Colon temperature 
was measured every hour for 9 h starting from PACAP-38-AB treatment. 
3. In studies with noraminophenazone on the hyperthermic effect of PACAP-38, 
noraminophenazone was administered IM once 30 min before ICV peptide treatment 
(PACAP-38 being injected in a dose of 1000 ng) and the colon temperature was measured 
1,2, 3,4, 5 and 6 h later. 
2.7 Statistical analysis 
Statistical analysis of the data was made by analysis of variance (ANOVA). For 
significant interactions (time x treatment) with two-way ANOVA, one-way ANOVA was 
performed, and then groups were compared by Tukey's post hoc test for multiple comparisons 
with unequal cell size. A probability level of 0.05 was accepted as indicating significant 
differences. 
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3 Results 
3.1 The effects of ANP-28, BNP-32 and CNP-22 on body temperature 
3.1.1 Hyperthermic effects of different doses of natriuretic peptides 
The effects of different doses of natriuretic peptides on the colon temperature were 
measured after ICV injections of dose-series of ANP-28, BNP-32 or CNP-22. 400 ng 
(131 pmol) and 1000 ng (327 pmol) doses of ANP-28 had a hyperthermic effect 30 min [F(3, 
33) = 40.56; p < 0.05], 60 min [F(3, 33) = 77.94; p < 0.05] and 90 min [F(3, 33) = 15.56; p < 
0.05] after ICV administration, the magnitude of the effect being smaller at 90 min than at 60 
min. ANP-28 in a dose of 40 ng (13.1 pmol) increased the colon temperature only at 60 min 
(Fig. 4). 
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Figure 4 
The effects of atrial natriuretic peptide (ANP) on colon temperature 
Control (9) 
40 ng A N P (10) 
400 ng A N P (9) 
1000 ng ANP (9) 
* * * 
* * * 
ANP groups of rats (n > 9) received an injection of ANP-28 (40, 400 or 1000 ng, ICV). The control group 
received an ICV injection of saline. Number of animals per group is presented in parentheses after the 
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corresponding group. The vertical lines denote the S.E.M. * p < 0.05, compared with the control; ** p < 0.05, 
compared with the control and with the 40 ng ANP group; *** p < 0.05, compared with the control and with the 
40 and 400 ng ANP groups. 
Both 400 (11.6 pmol) and 1000 ng (290 pmol) BNP-32 increased the colon temperature at 30 
min [F(3, 53) = 32.63; p < 0.05], 60 min [F(3, 53) = 41.83; p < 0.05] and 90 min [F(3, 53) = 
6.5; p < 0.05] (Fig. 5). 
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Figure 5 
The effects of brain natriuretic peptide (BNP) on colon temperature 
BNP groups of rats (n > 10) received an injection of BNP-32 (40, 400 or 1000 ng, ICV). The control group 
received an ICV injection of saline. Number of animals per group is presented in parentheses after the 
corresponding group. The vertical lines denote the S.E.M. * p < 0.05, compared with the control and with the 40 
ng BNP group. 
CNP-22 in doses of 400 ng (182 pmol) and 1000 ng (455 pmol) was hyperthermic both 30 
min [F(3, 34) = 15.72; p < 0.05] and 60 min [F(3, 34) = 28.48; p < 0.05] after ICV 
administration. The 1000 ng dose of CNP-22 was also hyperthermic at 90 min [F(3, 34) = 
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4.54; p < 0.05], A 40 ng (18.2 pmol) dose of CNP-22 had a mild, but statistically not 
significant hyperthermic effect (Fig. 6). 
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Figure 6 
The effects of C-type natriuretic peptide (CNP) on colon temperature 
CNP groups of rats (n > 9) received an injection of CNP-22 (40, 400 or 1000 ng, ICV). The control group 
received an ICV injection of saline. The vertical lines denote the S.E.M. * p < 0.05, compared with the control 
and with the 40 ng CNP group; ** p < 0.05, compared with the control and with the 40 and 400 ng CNP groups. 
3.1.2 Comparison of the hyperthermic effects of the most efficacious doses of natriuretic 
peptides 
Hyperthermic effects of ICV injections of a 1 pg dose of ANP-28, BNP-32 and CNP-
22 were compared. A 1 pg dose of either ANP-28, BNP-32 or CNP-22 had hyperthermic 
effects 30 min [F(3, 47) = 18.26; p < 0.01], 60 min [F(3, 47) = 20.36; p < 0.01] and 90 min 
[F(3, 47) = 10.61; p < 0.05] after ICV administration, the magnitude of the effect being 
smaller at 90 min than at 30 and 60 min. The probability level of the statistically significant 
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differences as compared to the control group were lower (p <0.01) for ANP-28 and CNP-22 
than for BNP-22 (p < 0.05) at 90 min, but no statistically significant difference could be 
demonstrated for BNP-22 as compared to the ANP-28 and CNP-22 groups at any time point 
(Fig. 7). These observations were in accordance with our previously published data (78). 
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Figure 7 
The effects of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type 
natriuretic peptide (CNP) on colon temperature 
Groups of rats (n > 12) received an injection of ANP-28, BNP-32 or CNP-22 (1 pg, ICV). The control group 
received an ICV injection of saline. Number of animals per group is presented in parentheses after the 
corresponding group. The vertical lines on the top of the bars denote the S.E.M. * p < 0.01, compared with the 
control; ** p < 0.05, compared with the control. 
3.2 The effects of noraminophenazone on the natriuretic peptide-induced hyperthermia 
The possible involvements of cyclooxygenase products in the natriuretic peptide-
induced hyperthermia were investigated. A 50 mg/kg IM injection of the cyclooxygenase 
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inhibitor noraminophenazone 30 min before peptide administration abolished the 
hyperthermic effects of 400 and 1000 ng ANP-28 [F30;60;90 min(5, 44) = 27.94; 43.30; 7.52; p < 
0.05] (Fig. 8), BNP-32 [F30;60;90min(5, 44) = 21.05; 32.25; 3.11; p < 0.05] (Fig. 9) and CNP-22 
[F3o;60;90 min(5, 45) = 49.25; 113.18; 0.91; p < 0.05] (Fig. 10). Noraminophenazone alone in a 
dose of 50 mg/kg IM did not affect the body temperature. 
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Figure 8 
Inhibitory effect of noraminophenazone on ANP-induced hyperthermia 
Groups of rats (n > 8) received an IM injection of saline (ANP groups) or 50 mg noraminophenazone (ANP + 
noraminophenazone groups) 30 min before an ICV injection of 400 or 1000 ng ANP-28. The 
noraminophenazone group received an ICV saline injection 30 min after noraminophenazone pretreatment (50 
mg, IM). The control group received an IM saline injection 30 min before saline treatment (ICV). The vertical 
lines at the top of the bars denote the S.E.M. * p < 0.05, compared with the control and with the 
noraminophenazone, the 400 ng ANP + noraminophenazone and the 1000 ng ANP + noraminophenazone 
groups; ** p < 0.05, compared with the control and with the noraminophenazone, the 400 ng ANP, the 400 ng 
ANP + noraminophenazone and the 1000 ng ANP + noraminophenazone groups. 
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Figure 9 
Inhibitory effect of noraminophenazone on BNP-induced hyperthermia 
Groups of rats (n > 8) received an IM injection of saline (BNP groups) or 50 mg noraminophenazone (BNP + 
noraminophenazone groups) 30 min before an ICV injection of 400 or 1000 ng BNP-32. The 
noraminophenazone groups received an ICV saline injection 30 min after noraminophenazone pretreatment (50 
mg, IM). The control group received an IM saline injection 30 min before saline treatment (ICV). The vertical 
lines at the top of the bars denote the S.E.M. * p < 0.05, compared with the control and with the 
noraminophenazone, the 400 ng BNP + noraminophenazone and the 1000 ng BNP + noraminophenazone 
groups. 
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Figure 10 
Inhibitory effect of noraminophenazone on CNP-induced hyperthermia 
Groups of rats (n > 8) received an IM injection of saline (CNP groups) or 50 mg noraminophenazone (CNP + 
noraminophenazone groups) 30 min before an ICV injection of 400 or 1000 ng CNP-22. The 
noraminophenazone group received an ICV saline injection 30 min after noraminophenazone pretreatment (50 
mg, IM). The control group received an IM saline injection 30 min before saline treatment (ICV). The vertical 
lines at the top of the bars denote the S.E.M. * p < 0.05, compared with the control and with the 
noraminophenazone, the 400 ng CNP + noraminophenazone and the 1000 ng CNP + noraminophenazone 
groups; ** p < 0.05, compared with the control and with the noraminophenazone, the 400 ng CNP, the 400 ng 
CNP + noraminophenazone and the 1000 ng CNP + noraminophenazone groups. 
3.3 The effects of isatin on the natriuretic peptide-induced hyperthermia 
A 50 mg/kg IP injection of the endogenous indole isatin 30 min before peptide 
administration abolished the hyperthermic effects of 1 pg ANP-28 [F3o;60;90 min(3, 34) = 25.39; 
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50.15; 13.93; p < 0.01] (Fig. 11), BNP-32 [ F 3 0 ; 6 0 min(3 , 38) = 17.05; 21.58; p < 0.01], 
[F9omin(3, 38) = 4.75; p < 0.05](Fig. 12) and CNP-22 [F 3 0 ; 60 ;90 min(3, 37) = 18.64; 23.02; 
11.80; p < 0.01] (Fig. 13). Isatin alone in a dose of 50 mg/kg IP did not affect the body 
temperature. 
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Figure 11 
Inhibitory effect of isatin on ANP-induced hyperthermia 
Groups of rats (n > 9) received an IP injection of saline (ANP group) or 50 mg isatin (isatin + ANP group) 30 
min before an ICV injection of 1 pg ANP-28. The isatin group received an ICV saline injection 30 min after 
isatin pretreatment (50 mg, IP). The control group received an IP saline injection 30 min before saline treatment 
(ICV). Number of animals per group is presented in parentheses after the corresponding group. The vertical lines 
at the top of the bars denote the S.E.M. * p < 0.01, compared with the control, the isatin and with the isatin + 
ANP groups. 
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Figure 12 
Inhibitory effect of isatin on BNP-induced hyperthermia 
Groups of rats (n > 10) received an IP injection of saline (BNP group) or 50 mg isatin (isatin + BNP group) 30 
min before an ICV injection of 1 pg BNP-32. The isatin group received an ICV saline injection 30 min after 
isatin pretreatment (50 mg, IP). The control group received an IP saline injection 30 min before saline treatment 
(ICV). Number of animals per group is presented in parentheses after the corresponding group. The vertical lines 
at the top of the bars denote the S.E.M. * p < 0.01, compared with the control, the isatin and with the isatin + 
BNP groups; ** p < 0.05, compared with the control, the isatin and with the isatin + BNP groups. 
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Figure 13 
Inhibitory effect of isatin on CNP-induced hyperthermia 
Groups of rats (n > 10) received an IP injection of saline (CNP group) or 50 mg isatin (isatin + CNP group) 30 
min before an ICV injection of 1 pg CNP-22. The isatin group received an ICV saline injection 30 min after 
isatin pretreatment (50 mg, IP). The control group received an IP saline injection 30 min before saline treatment 
(ICV). Number of animals per group is presented in parentheses after the corresponding group. The vertical lines 
at the top of the bars denote the S.E.M. * p < 0.01, compared with the control, the isatin and with the isatin + 
CNP groups. 
3.4 The effects of PACAP-38 on body temperature and the effects of PACAP-38-AB on 
colon temperature and on the PACAP-38-induced hyperthermia 
3.4.1 The effects of PACAP-38 on body temperature 
Both 500 and 1000 ng doses of PACAP-38 had hyperthermic effects 3, 4, 5 and 6 h 
[F3;4;5;6h(3, 38) = 25.85; 33.69; 24.38; 34.54; p < 0.05] after ICV administration. The 1000 ng 
dose of PACAP-38 was significantly more potent in increasing the colon temperature than the 
lower dose. There was a significant rise in colon temperature 2 h after the 1000 ng injection of 
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PACAP-38 [F (3, 38) = 3.31; p < 0.05]. A moderate decrease in the colon temperature was 
observed at 6 h in the PACAP-38-treated (500 or 1000 ng, ICV) animals. A 250 ng dose of 
PACAP-38 had no effect (Fig. 14). No change in body temperature compared to the initial 
values could be observed in any group 24 h after the administration of PACAP-38. 
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Figure 14 
Effects of PACAP-38 on colon temperature 
PACAP groups of rats received an injection of PACAP-38 (250, 500 or 1000 ng, ICV). The control group 
received an ICV injection of saline. Number of animals per group is presented in parentheses after the 
corresponding group. The vertical lines on the top of the marks denote the S.E.M. * p < 0.05, compared with the 
control; ** p < 0.05, compared with the control and with the PACAP 500 ng group. 
3.4.2 The effects of PACAP-38-AB on colon temperature and on the PACAP-38-induced 
hyperthermia 
None of the three dilutions of PACAP-38-AB (1:5, 1:10 and 1:20) modified the colon 
temperature of rats when given ICV 3 h before ICV saline injection (data not shown). Central 
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injections of PACAP-38-AB in dilutions of 1:5 and 1:10 3 h before PACAP-38 administration 
(1000 ng, ICV) completely abolished the hyperthermic effect of PACAP-38 [Fi; 2; 3; y s; 6; 7; 8; 9 
h (8, 58) = 1.26, 0.62, 0.42, 2.42, 9.16, 45.30, 99.77, 68.30, 63.48]. In accordance with 
expectations, ICV injections of the different (1:5, 1:10 and 1:20) dilutions of rabbit serum 3 h 
before saline treatment (ICV) had no effect on the colon temperature, and it did not modify 
the PACAP-38-induced hyperthermia (Fig. 15). 
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Figure 15 
Effects of PACAP-38 antiserum (PACAP-38-AB) on body temperature and on PACAP-
induced hyperthermia 
Groups of rats received an ICV injection of saline or different dilutions (1:5, 1:10 or 1:20) of either PACAP-38-
AB (antiserum + PACAP groups) or normal rabbit serum 3 h before (at 0 h) PACAP-38 (1000 ng, ICV) or saline 
(ICV) treatment (at 3h). (Groups of animals receiving different dilutions of PACAP-38-AB 3 h before an ICV 
saline injection are not shown). Number of animals per group is presented in parentheses after the corresponding 
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group. The vertical lines on the top of the bars denote the S.E.M. * p < 0.05, compared with the rabbit serum + 
saline group. 
3.5 The effects of noraminophenazone on the PACAP-38-induced hyperthermia 
A 50 mg/kg IM injection of the cyclooxygenase inhibitor noraminophenazone 30 min 
before peptide administration abolished the hyperthermic effect of 1000 ng PACAP-38 [F \-2-
3; 4; 5; 6 h (3, 31) - 0.45; 9.97; 44.89; 105.29; 51.31; 56.75; p < 0.05], Noraminophenazone 
alone in a dose of 50 mg/kg IM did not affect the body temperature (Fig. 16). 
Time (h) 
Figure 16 
Effects of noraminophenazone on PACAP-38-induced hyperthermia 
Groups of rats received an IM injection of saline (PACAP-38 group) or 50 mg noraminophenazone (combined 
group) 30 min before an ICV injection of 1000 ng PACAP-38. The noraminophenazone group received an IM 
injection of noraminophenazone (50 mg) 30 min before an ICV saline injection. The control group received an 
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IM saline injection 30 min before saline treatment (ICV). Number of animals per group is presented in 
parentheses after the corresponding group. The vertical lines on the top of the bars denote the S.E.M. * p < 0.05, 
compared with the control group. 
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4 Discussion 
Body temperature is regulated and monitored by specific regions of the CNS, and 
particularly regions of the anterior hypothalamus, which acts as a thermostat by altering the 
balance of heat loss and production via the sympathetic nervous system. Inflammatory 
processes in the organism induce certain host responses that are collectively referred to as the 
acute-phase response. An elevation of body temperature is part of this response. Mediators of 
this hyperthermia are some of the same mediators that account for other manifestations of the 
acute-phase response. 
Cytokines are pleiotropic molecules mediating a number of pathologic processes. 
Pyrogenicity is a fundamental biological property of several cytokines, such as IL-1 (27, 41) 
and IL-6 (39, 58), which stimulate thermogenesis at least partially via the synthesis of 
prostaglandins (30, 70, 88), however the mechanism by which pyrogens in the circulation 
promote the appearance of these metabolites of the cyclooxygenase pathway in the brain is 
not clear (24). Antipyretic drugs reduce fever by blocking the production of specific 
prostaglandins, and in particular P G E 2 , although there are data that support the hypothesis on 
non-steroid anti-inflammatory drugs (NSAID) producing their antipyresis at least partially via 
stimulation of AVP release or action (1,47). 
Some endogenously produced peptides have been found to affect the body temperature 
when administered to experimental animals (22). Those that can be found in the CNS are of 
overriding importance, since they may be involved in thermoregulatory processes under 
physiological conditions. Numerous studies have reported on neuropeptides, which can affect 
body temperature under experimental circumstances, but their physiological importance 
remains unclear (17, 33,45,48, 53, 64, 74, 79, 97). 
Since members of the natriuretic peptide family, PACAP and receptors for these 
peptides are all present in the brain, and it is widely accepted that these neuropeptides have 
significant roles in neuroendocrine regulation at a central level, in our experiments we 
investigated the possible participation of PACAP and natriuretic peptides in thermoregulation. 
Our data connected hyperthermic effects of these peptides to some known mediators of in 
vivo hyperthermic events. 
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4.1 The effects of ANP-28, BNP-32 and CNP-22 on body temperature 
The effects of centrally administered natriuretic peptides on body temperature have 
been revealed in this series of experiments. Injections of ANP-28, BNP-32 or CNP-22 into the 
lateral ventricle of the brain elevated the body temperature of the experimental animals. A 
positive correlation between the hyperthermic effect and the dose of peptide administration 
could be observed for ANP-28 and CNP-22. 
Several authors have investigated the distributions of ANP and related peptides and 
their receptors in the CNS. The central presence and localization of these peptides and their 
receptors has been identified, and it is now widely accepted that natriuretic peptides 
participate in neuroendocrine regulation and also that some of them may act in 
neuromodulation between glial cells and neurons (57, 104). ANP and CNP-encoding 
messenger RNA-positive neurons have been successfully detected in the medial preoptic area 
of the hypothalamus (a brain region that is known to take part in temperature control) in rats 
(83). 
Our results indicate that all members of the natriuretic peptide family cause 
hyperthermia when administered into the rat brain. Nevertheless, no other data are yet 
available to demonstrate that natriuretic peptides affect thermoregulatory events in the CNS. 
The comparison of the hyperthermic effects of the most efficacious doses of ANP and 
related peptides showed that the doses of the different types of natriuretic peptides used had 
similar hyperthermic potency. 
Despite that the administered effective doses of ANP and related peptides in our 
experiments are above the physiological range, the possible participation of a pathway 
involving natriuretic peptides in hyperthermic events under pathological conditions is not to 
be precluded. The localization of the site of hyperthermic action in the CNS as well as the 
route(s) of natriuretic peptides from the cerebroventricle to the active site are both to be 
identified to make the ICV doses of these peptides comparable to physiological ranges. 
Although CNP was reported to be the major natriuretic peptide in human cerebrospinal fluid 
(46), our results suggest that ANP-28 and BNP-32 may also have neuroendocrine actions in 
the CNS. 
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4.2 The effects of noraminophenazone on the natriuretic peptide-induced hyperthermia 
Possible participations of cyclooxygenase-products in the mediation of natriuretic 
peptides-induced hyperthermia were tested by the inhibition of the cyclooxygenase-pathway 
of the arachidonate cascade with a NSAID. The inhibition of prostaglandin production by 
noraminophenazone - a known inhibitor of prostaglandin synthesis (18) completely 
abolished the hyperthermia induced by ANP and related peptides. 
Connections between natriuretic peptides and prostaglandins were recently reported. 
Effects of ANP and a circulating peptide portion (ANP-31-67) of pro-ANP mediated by the 
generation of PGE2 were found in the kidney (38,44,105), and ANP, which increases cellular 
cyclic GMP by activating membrane-bound guanylate cyclase, was suggested to amplify the 
IL-ip-induced cyclooxygenase-2 mRNA expression (96). Bone endothelial cells have been 
demonstrated to bear receptors for natriuretic hormones associated with changes in 
prostaglandin production (28). 
Our data establish connections of ANP and related peptides with generally admitted 
pyrogenic substances - although it is still debatable, in view of a review (51), that 
prostaglandins themselves are essential for the development of all hyperthermic events. These 
results ascertain the participation of arachidonate metabolites of the cyclooxygenase-pathway 
in the mediation of the hyperthermia induced by natriuretic peptides in rats even though we 
are not aware of any direct evidence on other prostaglandin-mediated natriuretic peptide-
effects in the CNS. 
4.3 The effects of isatin on the natriuretic peptide-induced hyperthermia 
The effects of isatin on centrally administered natriuretic peptide-induced 
hyperthermia in rats have been revealed in this series of experiments. Injections of ANP-28, 
BNP-32 or CNP-22 into the lateral cerebroventricle elevated the body temperature of the 
animals, the doses of the different types of natriuretic peptides used having similar 
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hyperthermic potency. Isatin in a dose which itself had no effect on the basal body 
temperature completely abolished the hyperthermia induced by ANP and related peptides 
lending further support to the view that isatin antagonizes the action of the natriuretic peptides 
at a central level. 
Increasing evidence suggests that connections exist between the endogenous indole 
isatin and members of the natriuretic peptide system. Investigations undertaken to explore the 
interactions of isatin with natriuretic peptides in vivo have focused on water balance (9) and 
anxiety (86). Although isatin has been found to counteract some effects of these 
neuropeptides, to our knowledge no other data are yet available to demonstrate that isatin 
affects central actions of natriuretic peptides in vivo. 
Our previous results suggested that the possible participation of natriuretic peptides in 
thermoregulatory processes might be mediated via a pathway involving cyclooxygenase 
products (78), but we are not aware of any direct evidence concerning interactions between 
isatin and prostaglandins. Despite the presented evidence that isatin inhibits the hyperthermic 
effects of ANP and related peptides, the pathways that mediate the hyperthermic action of 
natriuretic peptides require further investigation. 
In summary, it can be concluded that in rats under experimental circumstances 
centrally administered natriuretic peptides induce hyperthermia with an early onset and a 
decline by 90 min. An as yet uncharacterized mechanism that can be inhibited by isatin 
(probably at the level of natriuretic peptide receptors) and includes cyclooxygenase products 
is suspected of mediating the hyperthermia induced by ANP and related peptides. Our 
findings — beyond the view that isatin acts on the ANP receptor, which was based upon in 
vitro results (69) - produce evidences that isatin can also inhibit effects of other members of 
the natriuretic peptide family in vivo. 
4.4 The effects of PACAP-38 on body temperature and the effects of PACAP-38-AB on 
colon temperature and on the PACAP-38-induced hyperthermia 
Counteracting effects of ICV administered PACAP-38 and thyrotropin-releasing 
hormone (TRH) but not VIP on the reserpine-induced hypothermia in murines have recently 
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been reported (61). An increase in the body temperature of reserpine-injected mice to the 
normal control level (37.8 ± 0.1 °C) 120 min after administration of the peptide was observed. 
PACAP was 500 times more potent than TRH in recovering reserpine-induced hypothermia in 
this study. It was suggested in consequence that PACAP might play an important role in 
regulating body temperature in the CNS. In spite of the presented evidence that PACAP has a 
direct action on hypothermia, to our knowledge no other data are yet available to demonstrate 
that PACAP affects thermoregulatory events in the CNS. 
The effects of centrally administered PACAP-38 on body temperature have been 
revealed in the first series of our experiments. Injections of the peptide into the lateral 
ventricle of the brain elevated the body temperature of the experimental animals with an onset 
of the hyperthermia at 2 h and a decline at 6 h. A positive correlation was observed between 
the hyperthermic effect and the dose of peptide administered. 
In order to show the specificity of the hyperthermic action for PACAP-38, we 
investigated the effects of PACAP-38-AB on PACAP-38-induced hyperthermia. We found 
that pretreatment with PACAP-38-AB completely prevented the development of hyperthermia 
in PACAP-38-treated animals, whereas PACAP-38-AB did not modify the body temperature 
itself. The latter findings do not support an endogenous role of PACAP-38 in the control of 
body temperature within normal ranges, but show that the hyperthermic effect of PACAP is 
selective to PACAP-38, and may suggest a participation of PACAP-38 under 
pathophysiological circumstances. 
In our experiments we found that the course of the hyperthermia induced by PACAP-
38 differs from those induced by natriuretic peptides considering that PACAP-38 induces 
hyperthermia vsjith a later onset and a longer duration than natriuretic peptides. 
Some investigators demonstrated delayed or atypical neuroendocrine actions of 
PACAP. On dispersed rat anterior pituitary cells, PACAP-38 was significantly effective 
(probably through protein kinase-C activation) on the release and synthesis of luteinizing 
hormone after 4h . PACAP-38 effects on GH and corticotropin levels (probably via IL-6 
production) did not reach significance until 24 h implying different but uncharacterized 
mechanisms of PACAP action (39). Others suggested a time-dependent paracrine action of 
PACAP by showing that a prolonged (38 h) static incubation of a total pituitary cell 
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suspension with PACAP-38 resulted in increased messenger RNA in prolactine and GH cells 
(99). 
On the grounds of the above findings the time characteristics of the PACAP-38-
induced hyperthermia raise the possibility of the involvement of time-consuming paracrine 
actions on different cell types in the hyperthermic effect of PACAP-38. 
4.5 The effects of noraminophenazone on the PACAP-38-induced hyperthermia 
Connections between PACAP and prostaglandins have been explored in some species. 
Although increasing concentrations of PACAP-38 are reported to evoke dose-response 
enhancement of PGE2 production in the testis of the rat (81), no data on the rat brain are yet 
available as concerns PACAP directly increasing P G E 2 synthesis. 
Our experiments revealed that the inhibition of prostaglandin synthesis with the 
cyclooxygenase inhibitor noraminophenazone completely abolished the hyperthermia induced 
by PACAP-38. 
Data have recently been presented on the PACAP type I receptor on macrophages 
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probably involved in controlling certain inflammatory responses (87). It was reported that 
maxadilan, a selective agonist of the PACAP type I receptor, inhibited TNF-a, but increased 
the IL-6 (a proinflammatory cytokine) and P G E 2 release of LPS-stimulated macrophages. 
PACAP-38 had the same effects as maxadilan on cytokine production. In another study, 
PACAP and VIP were found to enhance the secretion of IL-6 both in unstimulated 
macrophages and in macrophages stimulated with low (1-10 pg/ml) LPS concentrations (60). 
An earlier study reported the synergism of PACAP with IL-1 to stimulate IL-6 
secretion in rat astrocytes (35). These stimulatory effects of PACAP and IL-1 were similar to 
that of LPS on IL-6 secretion. 
Wang et al. (100) presented data on PACAP participating in ocular inflammation in 
the rabbit. Zhang et al. (106) found that the expression of PACAP is upregulated in sensory 
neurons by inflammation, and it is therefore suggested by the above authors that PACAP is 
likely to be involved in the inflammatory response. 
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Taken together, these data on the connections between endogenous pyrogens and 
PACAP lend support to our findings as regards the effects of PACAP on body temperature 
and also to the idea that PACAP might be involved in the inflammatory response. 
These results reinforce the significance of the participation of PACAP in 
neuroendocrine regulation. However the hyperthermic doses of the peptide does not suggest a 
physiological function of PACAP in thermoregulation, the judgment of the required ICV dose 
of the peptide for a physiological role is hampered by the factors mentioned above (see p. 30). 
Our study presents direct evidence that this neuropeptide can increase body temperature, and 
it is possible that in certain pathophysiological processes, which might release PACAP, it can 
cause fever via a pathway involving cyclooxygenase products. 
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5 Summary 
The main findings of our experiments: 
1) Centrally administered ANP-28, BNP-32 and CNP-22 induce hyperthermia in the 
laboratory rat with a decline of the hyperthermic effect by 90 min after peptide 
administration. Natriuretic peptides may participate in hyperthermic events within the 
CNS. 
2) The cyclooxygenase inhibitor noraminophenazone completely abolishes the natriuretic 
peptides-induced hyperthermia. Prostaglandin products of the arachidonate cascade 
may contribute to the mediation of the hyperthermic effects of natriuretic peptides in 
the rat. 
3) The endogenous indole isatin - probably by acting on natriuretic peptide receptors -
abolishes the natriuretic peptides-induced hyperthermia in the rat. Receptors, which 
can be inhibited with isatin, are expected to mediate the hyperthermic effects of 
natriuretic peptides. 
4) PACAP-38, when administered centrally, induces hyperthermia in rats and may play a 
role in hyperthermic events in pathophysiological processes. The time-course of the 
hyperthermia suggests time-consuming actions in the mediation of the hyperthermic 
effect of PACAP-38. 
5) The inhibition of the cyclooxygenase pathway of the arachidonate cascade abolishes 
the PACAP-38-induced hyperthermia in rats. Prostaglandin products are suggested to 
participate in the mediation of the hyperthermia induced by PACAP-38. 
Our experiments were designed to investigate the actions of neuropeptides (ANP-28, 
BNP-32, CNP-22, PACAP-38) on the central control of body temperature and to characterize 
the mediations of their achievable thermoregulatory effects in rats. 
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We demonstrated that ANP-28, BNP-32, CNP-22 and PACAP-38 can cause 
hyperthermia via pathways that involve cyclooxygenase products, and establish the inhibitory 
effects of isatin on in vivo actions of natriuretic peptides. Our results suggest that the 
examined neuropeptides may participate in hyperthermic events under at least 
pathophysiological circumstances and may contribute to the neuroendocrine regulation of 
body temperature. 
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